NUC-B
Trial Details
- Trial statusSetup
- Study email contactnucbtrial@imperial.ac.uk
- Chief InvestigatorProf Mark Thursz
- Project managerMariam Habib
- SponsorImperial College London
- ISRCTN numberTBC
- PhaseII
- View Trial Locations
Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance
Design and Objective
Multicentre, randomised, open label trial comparing two management strategies to promote HBsAg loss in patients with HBeAg negative chronic HBV infection. To explore whether finite treatment with nucleos(t)ide analogues is feasible in patients with HBeAg (Hepatitis B ‘e’ antigen) negative chronic HBV (Hepatitis B Virus) infection.
Key inclusion criteria
• Age ≥ 18 • Chronic HBV infection • HBeAg negative • Nucleos(t)ide analogues treatment for ≥3 years • HBV DNA < 400 IU/ml ≥2 years • Informed consent